千红制药(002550) - 2018 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2018 was ¥1,321,678,623.75, representing a 24.05% increase compared to ¥1,065,466,101.93 in 2017[23] - The net profit attributable to shareholders of the listed company was CNY 221,349,044.20, representing a 20.95% increase compared to the previous year[27] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 108,397,272.85, up 24.76% year-on-year[27] - Basic and diluted earnings per share were both CNY 0.17, reflecting a 21.43% increase from the previous year[27] - The total assets of the company increased by 4.40% to CNY 3,178,318,920.39 compared to the end of the previous year[27] - The net assets attributable to shareholders of the listed company rose by 3.81% to CNY 2,529,786,331.95[27] - The company reported quarterly revenue of CNY 338,085,544.70 in Q1, CNY 336,598,424.07 in Q2, CNY 329,447,307.73 in Q3, and CNY 317,547,347.25 in Q4[30] - The net profit attributable to shareholders in Q1 was CNY 84,075,310.30, while in Q4 it dropped to CNY 10,605,226.75[30] - The company achieved a total operating revenue of ¥1,321,678,623.75, representing a year-on-year increase of 24.05% compared to ¥1,065,466,101.93 in 2017[80] - The biopharmaceutical segment contributed ¥1,321,355,583.80, accounting for 99.98% of total revenue, with a year-on-year growth of 24.02%[82] - The raw material drug series generated ¥623,380,835.56, which is 47.17% of total revenue, showing a significant increase of 32.04% from the previous year[80] - Domestic revenue reached ¥783,186,998.94, representing 59.26% of total revenue, with a year-on-year increase of 15.79%[80] - International revenue was ¥538,491,624.81, accounting for 40.74% of total revenue, with a notable growth of 38.40% compared to the previous year[80] Profit Distribution - The profit distribution plan approved by the board is a cash dividend of ¥1.20 per 10 shares (including tax) for a total of 1,274,000,001 shares[6] - The company distributed cash dividends of RMB 152,880,000.12 (including tax) for 2018, which represents 69.07% of the net profit attributable to ordinary shareholders[148] - The cash dividend per 10 shares for 2018 was RMB 1.20, with no stock bonus shares issued[150] - The total distributable profit at the end of 2018 was RMB 1,050,133,545.39, ensuring that cash dividends accounted for 100% of the total profit distribution[153] - The cash dividend total for 2018, including other methods, was RMB 181,292,194.48, reflecting a strong commitment to shareholder returns[153] - The company has not issued any stock bonuses in the past three years, focusing solely on cash dividends for profit distribution[149] Risks and Challenges - The company faces various risks including drug bidding risks, new product development risks, and increased operational costs[6] - The company has optimized its internal control system, enhancing risk management in key operational areas such as environmental protection and quality control[75] - The company plans to enhance its internal control system to effectively prevent enterprise risks, focusing on quality, EHS, finance, and information security management[142] Business Operations and Development - The company has undergone changes in its main business scope, now including the production and sales of various pharmaceutical forms and diagnostic reagents[21] - The company has engaged Jiangsu Gongzheng Tianye Accounting Firm for auditing services during the reporting period[22] - The company has established a diversified marketing model combining self-operated sales, agency, and OTC sales, with over 600 professionals in its marketing team[47] - The international marketing system has been developed, with networks established in countries like the USA, Germany, France, Italy, and Japan, focusing on high-value product exports[47] - The company is actively involved in the development of innovative drugs and bioproducts to meet clinical needs and enhance production technology[51] - The company is one of the few domestic enterprises covering the entire heparin industry chain, with ongoing efforts to enhance product consistency and regulatory compliance[52] - The company has established a new production facility that is expected to commence operations following the completion of necessary certifications[113] Research and Development - The R&D investment for 2018 was ¥68,565,270.73, a 7.97% increase from ¥63,506,210.82 in 2017[98] - The number of R&D personnel increased to 160, a 5.96% rise from 151 in the previous year[98] - The company has filed 171 patents in biopharmaceutical innovation fields, with 71 patents granted, and has obtained three new drug production approvals and one clinical approval for a Class 1 new drug[61] - The company plans to improve R&D management capabilities and accelerate the speed of new product development in 2019[140] Market Performance - The company achieved nearly 500 million CNY in sales for the "Yikai" brand of kininogenase, enhancing its market influence and brand recognition[48] - Key products such as trypsin and heparin sodium have sales exceeding 500 million RMB, with market share continuously increasing[58] - The company has strengthened its market development for new products like enoxaparin, dalteparin, nadroparin calcium, and heparin sodium locking injection, laying a solid foundation for future growth[52] Corporate Governance and Compliance - The company has established a governance structure to protect the rights of shareholders and creditors, ensuring compliance with laws and regulations[196] - The company emphasizes employee welfare, providing various social insurances and fostering a harmonious labor relationship, recognized as a "Model Workers' Home" by the All-China Federation of Trade Unions[196] - The company has confirmed that there were no non-operating fund occupations by controlling shareholders or related parties[158] - The company has complied with all commitments made to minority shareholders in a timely manner[158] Financial Management - The company reported a total revenue of 1,685,069,100.00 CNY from investment-related activities, slightly down from 1,682,335,100.00 CNY in the previous year, indicating a decrease of approximately 0.2%[165] - The company has maintained a continuous relationship with Jiangsu Gongzheng Tianye Accounting Firm for 11 years, with an audit fee of 700,000 CNY for the current period[168] - There were no significant accounting errors that required retrospective restatement during the reporting period[166] - The company has not faced any major litigation or arbitration matters during the reporting period[172] - The company has not encountered any penalties or rectification issues during the reporting period[173] Investment and Capital Management - The company has committed to several investment projects, with a total committed investment of ¥62,463 million, of which ¥73,963 million has been adjusted[110] - The company has completed the expansion projects for trypsin raw materials and heparin sodium raw materials, with the completion of the asparaginase raw materials project pending due to site changes[113] - The company has returned CNY 5,500 million in bank loans, achieving 100% of the planned repayment[113] - The total raised funds directed towards various projects amounted to CNY 58,867.71 million, with a significant portion allocated to enhancing production capabilities[113]